Papers reviewed not cited H-R

  1. Hadi HA, Zubaid M, Al Mahmeed W, El-Menyar AA, Ridha M, Alsheikh-Ali AA, Singh R, Assad N, Al Habib K, Al Suwaidi J. Prevalence and prognosis of chronic obstructive pulmonary disease among 8167 Middle Eastern patients with acute coronary syndrome. Clin Cardiol. 2010 Apr;33(4):228-35
  2. Haesum LKE, Soerensen N, Dinesen B, Nielsen C, Grann O, Hejlesen O, Toft E, Ehlers L. Cost-Utility Analysis of a Telerehabilitation Program: A Case Study of COPD Patients. Telemedicine and e-Health 2012;18(9):688-692
  3. Hagstad S, Ekerljung L, Lindberg A, Backman H, Rönmark E, Lundbäck B. COPD among non-smokers – report from the obstructive lung disease in Northern Sweden (OLIN) studies. Respir Med. 2012 Jul;106(7):980-8
  4. Hajizadeh N, Crothers K, Braithwaite RS. A theoretical decision model to help inform advance directive discussions for patients with COPD. BMC Med Inform Decis Mak. 2010 Dec 20;10:75
  5. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist S, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006;28(3):523-32
  6. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, Macnee W, Make BJ, Rabe KF, Rennard SI, Sciurba FC, Silverman EK, Vestbo J, Washko GR, Wouters EF, Martinez FJ. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010 Sep 1;182(5):598-604
  7. Hannink JD, van Helvoort HA, Dekhuijzen PN, Heijdra YF. Dynamic hyperinflation during daily activities: does COPD global initiative for chronic obstructive lung disease stage matter? Chest. 2010 May;137(5):1116-21
  8. Hanrahan JP, Grogan DR, Baumgartner RA, Wilson A, Cheng H, Zimetbaum PJ, Morganroth J. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol. Medicine (Baltimore). 2008 Nov;87(6):319-28
  9. Hanson C, Rutten EPA, Wouters EFM, Rennard S. Diet and vitamin D as risk factors for lung impairment and COPD. Translational Research October 2013;162:219-236.
  10. Hareendran A, Palsgrove AC, Mocarski M, Schaefer ML, Setyawan J, Carson R, et al. The development of a patient-reported outcome measure for assessing night-time symptoms of chronic obstructive pulmonary disease. Health Qual Life Outcomes. 2013;11:104.
  11. Harris et al. Providing patients with reviews of evidence about COPD treatments: A controlled trial of outcomes. Chronic Respiratory Disease 2006;3:133-140
  12. Harris D, Hayter M, Allender S. Improving the uptake of pulmonary rehabilitation in patients with COPD: qualitative study of experiences and attitudes. Br J Gen Pract. 2008 Oct;58(555):703-10
  13. Harris M, Smith B, Veale A. Engaging patients in evidence-based medicine: development of a resource for people with chronic obstructive pulmonary disease. Chronic Illn 2005;1(4):330-6
  14. Hart JE, Eisen EA, Laden F. Occupational diesel exhaust exposure as a risk factor for chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2012 Mar;18(2):151-4
  15. Haruna A, Muro S, Nakano Y, Ohara T, Hoshino Y, Ogawa E, Hirai T, Niimi A, Nishimura K, Chin K, Mishima M. CT scan findings of emphysema predict mortality in COPD. Chest. 2010 Sep;138(3):635-40
  16. Harvey PA et al. Implementing evidence-based guidelines: inpatient management of chronic obstructive pulmonary disease. Intern Med J. 2005 Mar;35(3):151-5
  17. Haughney J, Gruffydd-Jones K, Roberts J, Lee AJ, Hardwell A, McGarvey L. The distribution of COPD in UK general practice using the new GOLD classification. Eur Respir J. 2014 Apr;43(4):993-1002.
  18. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009 Feb;11(2):130-9
  19. He ZY, Ou LM, Zhang JQ, Bai J, Liu GN, Li MH, Deng JM, MacNee W, Zhong XN. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration. 2010;80(6):445-52
  20. Hegewald MJ, Elliott CG. Sustained improvement with iloprost in a COPD patient with severe pulmonary hypertension. Chest 2009 Feb;135(2):536-7
  21. Herland K et al. How representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease? Respir Med. 2005 Jan;99(1):11-19
  22. Hill K, Dolmage TE, Woon LJ, Brooks D, Goldstein RS. Rollator use does not consistently change the metabolic cost of walking in people with chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2012 Jun;93(6):1077-80
  23. Hill K, Mathur S, Roig M, Janaudis-Ferreira T, Robles P, Dolmage TE, Goldstein R. Neuromuscular electrostimulation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No.: CD010821. DOI: 10.1002/14651858.CD010821.
  24. Holland AE, Hill CJ, Rasekaba T, Lee A, Naughton MT, McDonald CF. Updating the minimal important difference for six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2010 Feb;91(2):221-5
  25. Holland AE and Nici L. The return of the Minimum Clinically Important Difference for 6-minute walk distance in Chronic Obstructive Pulmonary Disease. Editorial. Am J Respir Crit Care Medicine 187 (4): 335-336.
  26. Hoogendoorn M, van Wetering CR, Schols AM, Rutten-van Mölken MP. Is INTERdisciplinary COMmunity-based COPD management (INTERCOM) cost-effective? Eur Respir J. 2010 Jan;35(1):79-87
  27. Hopkinson NS, Englebretsen C, Cooley N, Kennie K, Lim M, Woodcock T, Laverty AA, Wilson S, Elkin SL, Caneja C, Falzon C, Burgess H, Bell D, Lai D. Designing and implementing a COPD discharge care bundle.  Thorax. 2012 Jan;67(1):90-2
  28. Horie J, Murata S, Hayashi S, Murata J, Miyazaki J, Mizota K, Horikawa E. Factors that delay COPD detection in the general elderly population. Respir Care. 2011 Aug;56(8):1143-50
  29. Huang KW, Luo JC, Leu HB, Lin HC, Lee FY, Chan WL, Lin SJ, Chen JW, Chang FY. Chronic obstructive pulmonary disease: an independent risk factor for peptic ulcer bleeding: a nationwide population-based study. Aliment Pharmacol Ther. 2012 Apr;35(7):796-802. doi: 10.1111/j.1365-2036.2012.05028.x
  30. Hunninghake DB. Cardiovascular Disease in Chronic Obstructive Pulmonary Disease. Proc Am Thoracic Soc 2005;2(1):44-9
  31. Husereau D, Shukla V, Boucher M, Mensinkai S, Dales R. Long acting beta2 agonists for stable chronic obstructive pulmonary disease with poor reversibility: a systematic review of randomised controlled trials. BMC Pulm Med 2004;4:7
  32. Iftikhar IH, McGuire FR, Musani AI. Efficacy of bronchoscopic lung volume reduction: a meta-analysis. Int J Chron Obstruct Pulmon Dis. 2014; 9: 481–491.
  33. International Primary Care Respiratory Group (IPCRG). The use of long-acting beta2-agonists (LABAs) in asthma. IPCRG position statement following warnings from regulatory authorities including the US FDA. September 2006
  34. Iribarne A, Russo MJ, Ryan MS, Davies R, Hong KN, Gelijns AC, Bacchetta MD, D’Ovidio F, Arcasoy S, Sonett JR. Despite decreased wait-list times for lung transplantation, lung allocation scores continue to increase. Chest 2009;135:923–928
  35. Ivey, M., A., Johns, D., P., et al. Assessing the performance of two lung age equations on the Australian population: using data from the cross-sectional BOLD-Australia study. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco. 2014;16(12):1629-37.
  36. Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, Elsik M, Krum H, Hayward CS. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010 Apr 27;55(17):1780-7
  37. Jacome CI, Marques AS. Pulmonary rehabilitation for mild chronic obstructive pulmonary disease: a systematic review. Respir Care. 2013 Oct 8. [Epub ahead of print]
  38. Janaudis-Ferreira et al. Measurement of Activities of Daily Living in Patients With COPD A Systematic Review. CHEST 2014; 145(2):253–271
  39. Janssen DJ, Curtis JR, Au DH, Spruit MA, Downey L, Schols JM, Wouters EF, Engelberg RA. Patient-clinician communication about end-of-life care for Dutch and US patients with COPD. Eur Respir J. 2011 Aug;38(2):268-76
  40. Jehn M, Schmidt-Trucksäss A, Meyer A, Schindler C, Tamm M, Stolz D. Association of daily physical activity volume and intensity with COPD severity. Respir Med. 2011 Dec;105(12):1846-52
  41. Jenkins CR, Jones PW, Calverley PMA, Celli B, Anderson JA, Ferguson GT, Yates JC, Willits LR, Vestbo J. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respiratory Research 2009, 10:59 doi:10.1186/1465-9921-10-59
  42. Jithoo A, Enright PL, Burney P, Buist S, Bateman ED, Tan WC, Studnickae M, Mejza F, Gillespie S, Vollmer WM for the BOLD Collaborative Research Group. Case-finding options for COPD: results from the Burden of Obstructive Lung Disease Study. Eur Respir J 2013; 41: 548–555
  43. Johansson EL, Ternesten-Hasséus E, Olsén MF, Millqvist E. Respiratory movement and pain thresholds in airway environmental sensitivity, asthma and COPD. Respir Med. 2012 Jul;106(7):1006-13
  44. Jolliet P, Tassaux D, Roeseler J, Burdet L, Broccard A, D’Hoore W, Borst F, Reynaert M, Schaller M-D, Chevrolet J-C. Helium-oxygen versus air-oxygen non-invasive pressure support in decompensated chronic obstructive disease: A prospective multicenter study. Crit Care Med 2003; 31(3): 878-884
  45. Jones PW, Greenstone M. Carbonic anhydrase inhibitors for hypercapnic ventilatory failure in chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews 2001, Issue 1. Art. No.: CD002881. DOI: 10.1002/14651858:CD002881
  46. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014 Feb 1;189(3):250-5. doi:10.1164/rccm.201310-1863PP
  47. Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, Segarra R,  Caractae C, Garcia Gil E. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 2012; 40: 830–836
  48. Jones RC, Donaldson GC, Chavannes NH, Kida K, Dickson-Spillmann M, Harding S, Wedzicha JA, Price D, Hyland ME. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med. 2009 Dec 15;180(12):1189-95
  49. Jones RC, Price D, Ryan D, Sims EJ, von Ziegenweidt J, Mascarenhas L, Burden A, Halpin DM, Winter R, Hill S, Kearney M, Holton K, Moger A, Freeman D, Chisholm A, Bateman ED; Respiratory Effectiveness Group. Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. Lancet Respir Med. 2014 Apr;2(4):267-76.
  50. Jordan RE, Lam KB, Cheng KK, Miller MR, Marsh JL, Ayres JG, Fitzmaurice D, Adab P. Case finding for chronic obstructive pulmonary disease: a model for optimising a targeted approach. Thorax. 2010 Jun;65(6):492-8.
  51. Jordan N, Lee TA, Valenstein M, Weiss KB. Effect of care setting on evidence-based depression treatment for veterans with COPD and comorbid depression. J Gen Intern Med. 2007 Oct;22(10):1447-52. Epub 2007 Aug 9
  52. Joshia M, Joshia A, Bartter T. Symptom burden in chronic obstructive pulmonary disease and cancer. Curr Opin Pulm Med 2012, 18:97–103
  53. Kahn LS, Fox CH, Olawaiye A, Servoss TJ, McLean-Plunkett E. Facilitating quality improvement in physician management of comorbid chronic disease in an urban minority practice. J Natl Med Assoc. 2007 Apr;99(4):377-83
  54. Karish SB, Gagnon JM. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor. Ann Pharmacother 2006;40(6):1096-104
  55. Katelaris A. Editor’s Choice: Beyond reporting: the MJA takes an active role in improving health care. MJA 197(2) 16 July 2012: 65
  56. Keenan SP, Sinuff T, Cook DJ, Hill NS. Which patients with acute exacerbation of chronic obstructive pulmonary disease benefit from non-invasive positive-pressure ventilation? A systematic review of the literature. Ann Intern Med. 2003;138(11):861-70
  57. Kerwin EM, D’Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF on behalf of the ACCORD I study investigators. Efficacy and Safety of a 12-week Treatment with Twice-daily Aclidinium Bromide in COPD Patients (ACCORD COPD I). Journal of Chronic Obstructive Pulmonary Disease. 2012; 9:1–12
  58. Kerstjens HA, Bantje TA, Luursema PB, Sinninghe Damste HE, de Jong JW, Lee A, Wijker SP, Cornelissen PJ. Effects of short-acting bronchodilators added to maintenance tiotropium therapy. Chest 2007; 132: 1493-9.
  59. Kessler R, Stahl E, Vogelmeier C, Haughney J, Trudeau E, Lofdahl CG, Partridge MR. Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest 2006 Jul;130(1):133-42
  60. Kesten S, Celli B, Decramer M, Liu D, Tashkin D. Adverse health consequences in COPD patients with rapid decline in FEV1 – evidence from the UPLIFT trial.  Respiratory Research 2011, 12:129
  61. Kherad O, Kaiser L, Bridevaux PO, Sarasin F, Thomas Y, Janssens JP, Rutschmann OT. Upper-respiratory viral infection, biomarkers, and COPD exacerbations. Chest. 2010 Oct;138(4):896-904
  62. Kiakouama L, Cottin V, Glerant JC, Bayle JY, Mornex JF, Cordier JF. Conditions associated with severe carbon monoxide diffusion coefficient reduction. Respir Med. 2011 Aug;105(8):1248-56
  63. Kida K, Wakabayashi R, Mizuuchi T, Murata A. Screening for suspected chronic obstructive pulmonary disease with an eleven-item pre-interview questionnaire (11-Q). Intern Med 2006;45(21):1201-7
  64. Kikuchi H, Shiozawa N, Takata S, Ashida K, Mitsunobu F. Effect of repeated Waon therapy on exercise tolerance and pulmonary function in patients with chronic obstructive pulmonary disease: a pilot controlled clinical trial. International Journal of COPD 2014;9:9–15
  65. Kim C, Seo JB, Lee SM, Lee JS, Huh JW, Lee JH, Ra SW, Lee JH, Kim EK, Kim TH, Kim WJ, Lee SM, Lee SY, Lim SY, Shin TR, Yoon HI, Sheen SS, Oh YM, Park YB, Lee SD. Exertional desaturation as a predictor of rapid lung function decline in COPD. Respiration. 2013;86(2):109-16. doi: 10.1159/000342891. Epub 2012 Dec 11.
  66. Kim DK, Jacobson FL, Washko GR, Casaburi R, Make BJ, Crapo JD, Silverman EK, Hersh CP. Clinical and radiographic correlates of hypoxemia and oxygen therapy in the COPDGene study. Respir Med. 2011 Aug;105(8):1211-21
  67. Kim V, Kretschman DM, Sternberg AL, DeCamp MM Jr, Criner GJ; National Emphysema Treatment Trial Research Group. Weight gain after lung reduction surgery is related to improved lung function and ventilatory efficiency. Am J Respir Crit Care Med. 2012 Dec 1;186(11):1109-16. doi:10.1164/rccm.201203-0538OC. Epub 2012 Aug 9.
  68. Kim YJ, Lee BK, Jung CY, Jeon YJ, Hyun DS, Kim KC, Yu SK, Choi HS, Shin WH, Lee KH. Patient’s Perception of Symptoms Related to Morning Activity in Chronic Obstructive Pulmonary Disease: The SYMBOL Study. Korean J Intern Med 2012;27:426-435.
  69. Kitaguchi Y, Komatsu Y, Fujimoto K, Hanaoka M, Kubo K. Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. Int J Chron Obstruct Pulmon Dis. 2012;7:283-9. Epub 2012 Apr 12.
  70. Klijn P et al. Nonlinear exercise training in advanced chronic obstructive pulmonary disease is superior to traditional exercise training. A randomized trial. Am J Respir Crit Care Med 2013;188:193-200
  71. Kohansal R, Soriano JB, Agusti A. Investigating the natural history of lung function: facts, pitfalls, and opportunities. Chest. 2009 May;135(5):1330-41
  72. Kramer MR, Refaely Y, Maimon N, Rosengarten D, Fruchter O. Two-Year Follow-up in Patients Treated With Emphysematous Lung Sealant for Advanced Emphysema. Chest 2013;144(5):1677–1680
  73. Kreiss K, Esfahani RS, Antao VCS, Odencrantz J, Lezotte DC, Hoffman RE. Risk factors for asthma among cosmetology professionals in Colorado. J Occup Environ Med 2006;48(10):1062-1069
  74. Kruis AL, Boland MR, Assendelft WJ, Gussekloo J, Tsiachristas A, Stijnen T, Blom C, Sont JK, Rutten-van Mölken MP, Chavannes NH. Effectiveness of integrated disease management for primary care chronic obstructive pulmonary disease patients: results of cluster randomised trial. BMJ. 2014 Sep 10;349:g5392. doi: 10.1136/bmj.g5392.
  75. Kunik ME, Azzam PN, Souchek J, Cully JA, Wray NP, Krishnan LL, Nelson HA, Stanley MA. A practical screening tool for anxiety and depression in patients with chronic breathing disorders. Psychosomatics 2007 Jan-Feb;48(1):16-21
  76. Kunisaki KM, Rice KL, Niewoehner DE. Management of acute exacerbations of chronic obstructive pulmonary disease in the elderly : an appraisal of published evidence. Drugs Aging. 2007;24(4):303-24
  77. Kuschner WG, Hegde S, Agrawal M. Occupational history quality in patients with newly documented, clinician-diagnosed chronic bronchitis. Chest. 2009 Feb;135(2):378-83
  78. Lam DC, Hui CK, Ip MS. Issues in pulmonary function testing for the screening and diagnosis of chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2012 Mar;18(2):104-11
  79. Lange P, Marott JL, Vestbo J, Olsen KR, Ingebrigtsen TS, Dahl M, Nordestgaard BG. Prediction of the Clinical Course of Chronic Obstructive Pulmonary Disease, Using the New GOLD Classification A Study of the General Population. Am J Respir Crit Care Med 2012;186(10):975–981.
  80. Lapperre TS, Sont JK, Schadewijk A, Gosman MME, Postma DS, Bajema IM, Timens W, Mauad T, Hiemstra PS and the GLUCOLD Study Group. Smoking cessation and bronchial epithelial remodelling in COPD: a cross-sectional study. Respiratory Research 2007, 8:85 doi:10.1186/1465-9921-8-85
  81. Larsson K, Janson C, Lisspers K, Jørgensen L, Stratelis G, Telg G, Ställberg B, Johansson G. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study. J Intern Med. 2013 Jun;273(6):584-94. doi: 10.1111/joim.12067. Epub 2013 Apr 1.
  82. Le Cong M, Robertson A. A 3-year retrospective audit of the use of noninvasive positive pressure ventilation via the Oxylog 3000 transport ventilator during air medical retrievals. Air Med J. 2013 May-Jun;32(3):126-8. doi: 10.1016/j.amj.2012.10.016.
  83. Lee PN. Systematic review of the epidemiological evidence comparing lung cancer risk in smokers of mentholated and unmentholated cigarettes. BMC Pulmonary Medicine 2011, 11:18 doi:10.1186/1471-2466-11-18
  84. Lee TM, Lin MS, Chang NC. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol. 2008 Feb 15;101(4):530-5. Epub 2007 Dec 26
  85. Lee T-M, Chen C-C, Shen H-N, Chang NC. Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clin Sci (Lond). 2009;116(6):497-505
  86. Lee DS, Markwardt S, McAvay GJ, Gross CP, Goeres LM, Han L, Peduzzi P, Lin H, Dodson JA, Tinetti ME. Effect of β-blockers on cardiac and pulmonary events and death in older adults with cardiovascular disease and chronic obstructive pulmonary disease. Med Care. 2014 Mar;52 Suppl 3:S45-51.
  87. Leiva-Fernández J, Leiva-Fernández F, García-Ruiz A, Prados-Torres D, Barnestein-Fonseca P. Efficacy of a multifactorial intervention on therapeutic adherence in patients with chronic obstructive pulmonary disease (COPD): a randomized controlled trial. BMC Pulm Med. 2014 Apr 25;14:70.
  88. Leivseth L, Brumpton BM, Nilsen TI, Mai XM, Johnsen R, Langhammer A. GOLD classifications and mortality in chronic obstructive pulmonary disease: the HUNT Study, Norway. Thorax. 2013 Oct;68(10):914-21.
  89. Lemmens K, Strating M, Huijsman R, Nieboer A. Professional commitment to changing chronic illness care: results from disease management programmes. Int J Qual Health Care. 2009 Aug;21(4):233-42
  90. Lewis CA, Fergusson W, Eaton T, Zeng I, Kolbe J. Isolated nocturnal desaturation in COPD: prevalence and impact on quality of life and sleep. Thorax. 2009 Feb;64(2):133-8
  91. Lin K, MD, Watkins B, Johnson T, Rodriguez JA and Barton MB. Screening for Chronic Obstructive Pulmonary Disease Using Spirometry: Summary of the Evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;148:535-543
  92. Liu X-L et al. Effectiveness of home-based pulmonary rehabilitation for patients with chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials. Rehabilitation Nursing 2014: 39-69.
  93. Lord VM, Hume VJ, Kelly JL, Cave P, Silver J, Waldman M, White C, Smith C, Tanner R, Sanchez M, Man WD-C, Polkey MI, Hopkinson NS. Singing classes for chronic obstructive pulmonary disease: a randomized controlled trial. BMC Pulmonary Medicine 2012, 12:69 doi:10.1186/1471-2466-12-69.
  94. Louie S, Zeki AA, Schivo M, Chan AL, Yoneda KY, Avdalovic M, Morrissey BM, Albertson TE. The asthma–chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations Expert Rev Clin Pharmacol 2013;6(2):197–219.
  95. Lusuardi M, De Benedetto F, Paggiaro P, Sanguinetti CM, Brazzola G, Ferri P, Donner CF. A randomized controlled trial of office spirometry in asthma and COPD in standard general practice. Chest 2006;129(4):844-852
  96. Lykkegaard J, Søndergaard J, Kragstrup J, Rømhild Davidsen J, Knudsen T, Andersen M. All Danish first-time COPD hospitalisations 2002-2008: incidence, outcome, patients, and care. Respir Med. 2012 Apr;106(4):549-56
  97. Machado M-C L, Krishnan JA, Buist SA, Bilderback AL, Fazolo GP, Santarosa MG, Queiroga Jr. F, Vollmer WM. Sex differences in survival of oxygen-dependent patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2006;174:524-529
  98. MacNee W. Accelerated lung aging: a novel pathogenic mechanism of chronic obstructive pulmonary disease (COPD). Biochem Soc Trans. 2009 Aug;37(Pt 4):819-23
  99. Maddocks M, Gao W, Higginson IJ, Wilcock A. Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease. Cochrane Database of Systematic Reviews 2013, Issue 1. Art. No.: CD009419. DOI: 10.1002/14651858.CD009419.pub2.
  100. Maggiore SM, Richard JC, Abroug F, Diehl JL, Antonelli M, Sauder P, Mancebo J, Ferrer M, Lellouche F, Lecourt L, Beduneau G, Brochard L. A multicenter, randomized trial of noninvasive ventilation with helium-oxygen mixture in exacerbations of chronic obstructive lung disease. Crit Care Med. 2010 Jan;38(1):145-51
  101. Magnussen H, Verkindre C, Jack D, Jadayel D, Henley M, Woessner R, Higgins M, Kramer B, on behalf of the INPUT study investigators. Indacaterol once-daily is equally effective dosed in the evening or morning in COPD. Respiratory Medicine 2010;104:1869-1876
  102. Mahler DA, D’Urzo A, Bateman ED, Ozkan SA, White T, Peckitt C, Lassen C, Kramer B on behalf of the INTRUST-1 and INTRUST-2 study investigators. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012;67:781-788
  103. Maltais F et al. A Canadian, multicentre, randomized clinical trial of home-based pulmonary rehabilitation in chronic obstructive pulmonary disease: rationale and methods. Can Resp J. 2005 May-Jun;12(4): 193-8
  104. Mannino DM, Davis KJ, Kiri VA. Chronic obstructive pulmonary disease and hospitalizations for pneumonia in a US cohort. Respir Med. 2009 Feb;103(2):224-9
  105. Mannino DM, Diaz Guzman E, Buist S. Pre- and post-bronchodilator lung function as predictors of mortality in the Lung Health Study. Respiratory Research 2011, 12:136 doi:10.1186/1465-9921-12-136
  106. Marks GB. Are reference equations for spirometry an appropriate criterion for diagnosing disease and predicting prognosis? Thorax. 2012 Jan;67(1):85-7
  107. Martin SE, Bradley JM, Buick JB, Crossan A, Elborn JS. The effect of hypoxia on cognitive performance in patients with chronic obstructive pulmonary disease. Respir Physiol Neurobiol. 2011 Jun 30;177(1):36-40
  108. Martina SD, Ismail MS, Vesta KS. Cilomilast: orally active selected phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease. Ann Pharmacother 2006;40(10):1822-8
  109. Martinez FJ, Han MK, Andrei AC, Wise R, Murray S, Curtis JL, Sternberg A, Criner G, Gay SE, Reilly J, Make B, Ries AL, Sciurba F, Weinmann G, Mosenifar Z, DeCamp M, Fishman AP, Celli BR; National Emphysema Treatment Trial Research Group. Longitudinal change in the BODE index predicts mortality in severe emphysema. Am J Respir Crit Care Med. 2008 Sep 1;178(5):491-9
  110. Martínez-García MÁ, Soler-Cataluña JJ, Donat Sanz Y, Catalán Serra P, Agramunt Lerma M, Ballestín Vicente J, Perpiñá-Tordera M. Factors associated with bronchiectasis in patients with COPD. Chest. 2011 Nov;140(5):1130-7
  111. Mauskopf JA, Baker CL, Monz BU, Juniper MD. Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence. J Med Econ. 2010 Jul 8
  112. McCrory DC, Brown C, Gelfand SE, Bach PB. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest. 2001;119(4):1190-29
  113. McDonald VM, Higgins I, Wood LG, Gibson PG. Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? Thorax 2013;68:691–694
  114. McDonough JE, Yuan R, Suzuki M, Seyednejad N, Elliott WM, Sanchez PG, Wright AC, Gefter WB, Litzky L, Coxson HO, Paré PD, Sin DD, Pierce RA, Woods JC, McWilliams AM, Mayo JR, Lam SC, Cooper JD, Hogg JC. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med. 2011 Oct 27;365(17):1567-75
  115. McGarvey LP, Magder S, Burkhart D, Kesten S, Liu D, Manuel RC, Niewoehner DE. Cause-specific mortality adjudication in the UPLIFT COPD trial: Findings and recommendations. Respiratory Medicine 2012;106:515-521
  116. McKenna SP, Twiss J, Crawford SR, Oprandi NC, Tammaru M, Miravitlles M. The living with chronic obstructive pulmonary disease scale was successfully adapted for use in Southern European (Italian and Spanish) and Eastern European (Russian) cultures. J Clin Epidemiol. 2012 Aug;65(8):906-14. Epub 2012 May 5.
  117. McKenzie DK, Butler JE, Gandevia SC. Respiratory muscle function and activation in chronic obstructive pulmonary disease. J Appl Physiol. 2009 Aug;107(2):621-9. Epub 2009 Apr 23
  118. McNicholas WT, Calverley PMA, Lee A, Edwards JC on behalf of the Tiotropium Sleep Study in COPD Investigators. Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD Eur Respir J 2004; 23:825-831
  119. Menezes AM, Montes de Oca M, Pérez-Padilla R, Nadeau G, Wehrmeister FC, Lopez-Varela MV, Muiño A, Jardim JR, Valdivia G, Tálamo C; PLATINO Team. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma. Chest. 2014 Feb;145(2):297-304
  120. Menezes AM, Muiño A, López-Varela MV, Valdivia G, Lisboa C, Jardim JR, et al. A population-based cohort study on chronic obstructive pulmonary disease in Latin America: methods and preliminary results. The PLATINO Study Phase II. Arch Bronconeumol. 2014;50(1):10-7.
  121. Meyers BF, Patterson GA. Chronic obstructive pulmonary disease. 10: Bullectomy, lung volume reduction surgery, and transplantation for patients with chronic obstructive pulmonary disease. Thorax 2003 Jul; 58(7):634-8
  122. Michele TM, Pinheiro S, Iyasu S. The Safety of Tiotropium — The FDA’s Conclusions. NEJM 2010; 2010; 363:1097-1099
  123. Miller MR, Quanjer PH, Swanney MP, Ruppel G, Enright PL. Interpreting lung function data using 80% predicted and fixed thresholds misclassifies more than 20% of patients. Chest 2011;139(1):52–59
  124. Miller D, Fraser K, Murray I, Thain G, Currie GP. Predicting survival following non-invasive ventilation for hypercapnic exacerbations of chronic obstructive pulmonary disease. Int J Clin Pract. 2012 May;66(5):434-7. doi: 10.1111/j.1742-1241.2012.02904.x
  125. Miravitlles M, Marin A, Monso E, Vila S, de la Roza C, Herva R, Esquinas C, Garcia M, Millares L, Morera J, Torreshad A. Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD. Eur Respir J 2009;34: 1066–1071
  126. Mohamed Hoesein FA, Zanen P, Lammers JW. Lower limit of normal or FEV1/FVC < 0.70 in diagnosing COPD: an evidence-based review. Respir Med. 2011 Jun;105(6):907-15
  127. Molinos L, Clemente MG, Miranda B, Alvarez C, del Busto B, Cocina BR, Alvarez F, Gorostidi J, Orejas C; ASTURPAR Group. Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. J Infect. 2009 Jun;58(6):417-24
  128. Momen N, Hadfield P, Kuhn I, Smith E, Barclay S. Discussing an uncertain future: end-of-life care conversations in chronic obstructive pulmonary disease. A systematic literature review and narrative synthesis. Thorax 2012;67:777-780
  129. Monninkhof EM, van der valk PDLPM, van der Palen J, van Herwaarden CLA, Partridge MR, Waters EH, Zielhuis GA. Self-management education for chronic obstructive pulmonary disease The Cochrane Database of Systematic Reviews 2002, Issue 4. Art. No.: CD002990. DOI: 10.1002/14651858:CD002990
  130. Moy ML, Danilack VA, Weston NA, Garshick E. Daily step counts in a US cohort with COPD. Respir Med. 2012 Jul;106(7):962-9
  131. Mucha L, Stephenson J, Morandi N, Dirani R. Meta-analysis of disease risk associated with smoking, by gender and intensity of smoking. Gend Med. 2006 Dec;3(4):279-91
  132. Müllerova H, Chigbo C, Hagan GW, Woodhead MA, Miravitlles M, Davis KJ, Wedzicha JA. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med. 2012 Aug;106(8):1124-33. Epub 2012 May 22.
  133. Murphy PB, Brignall K, Moxham J, Polkey MI, Davidson AC, Hart N. High pressure versus high intensity noninvasive ventilation in stable hypercapnic chronic obstructive pulmonary disease: a randomized crossover trial. Int J Chron Obstruct Pulmon Dis. 2012;7:811-8. doi: 10.2147/COPD.S36151. Epub 2012 Dec 11.
  134. Naberan K, Azpeitia A, Cantoni J, Miravitlles M. Impairment of quality of life in women with chronic obstructive pulmonary disease. Respir Med. 2012 Mar;106(3):367-73
  135. Nathell L, Nathell M, Malmberg P, Larsson K. COPD diagnosis related to different guidelines and spirometry techniques. Respiratory Research 2007 8:89
  136. Ni W, Shao X, Cai X, Wei C, Cui J, Wang R, Liu Y. Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis. PLoS One. 2015 Mar 26;10(3):e0121257. doi: 10.1371/journal.pone.0121257. eCollection 2015.
  137. Nici L and ZuWallack R on behalf of the American Thoracic Society Subcommittee. An Official American Thoracic Society Workshop Report: The Integrated Care of the COPD Patient. Proc Am Thorac Soc. Mar 15, 2012 9 (1): 9–18.
  138. Niederman MS, Anzueto A, Sethi S, Choudhri S, Kureishi A, Haverstock D, Perroncel R. Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents. Respir Med. 2006 Oct;100(10):1781-90. Epub 2006 Mar 13
  139. Nield M, Hoo GW. Real-time telehealth for COPD self-management using Skype™. COPD. 2012 Dec;9(6):611-9. doi: 10.3109/15412555.2012.708067. Epub 2012 Sep 4.
  140. Niesink A, Trappenburg JC, de Weert-van Oene GH, Lammers JW, Verheij TJ, Schrijvers AJ. Systematic review of the effects of chronic disease management on quality-of-life in people with chronic obstructive pulmonary disease (Provisional record). Respiratory Medicine 2007; 101(11): 2233-2239
  141. Niewoehner DE, Lapidus R, Cote C, Sharafkhaneh A, Plautz M, Johnson P, Kesten S. Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2009 Dec;22(6):587-92
  142. Noda T, Ojima T, Hayasaka S, Hagihara A, Takayanagi R, Nobutomo K. The health impact of remarriage behavior on chronic obstructive pulmonary disease: findings from the US longitudinal survey. BMC Public Health 2009,9:412
  143. O’Donnell DE, Hernandez P, Aaron S, Bourbeau J, Marciniuk D, Hodder R, Balter M, Ford G, Gervais A, Goldstein R, Maltais F, Road J, McKay V, Schenkel J. Canadian Thoracic Society COPD Guidelines: Summary of highlights for family doctors. Can Respir J 2003;10(4):183-185
  144. O’Donnell DE, Casaburi R, Vincken W, Puente-Maestu L, Swales J, Lawrence D, Kramer B; INABLE 1 study group. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med. 2011;105(7):1030-6
  145. O’Driscoll BR, Neill J, Pulakal S, Turkington PM. A crossover study of short burst oxygen therapy (SBOT) for the relief of exercise-induced breathlessness in severe COPD. BMC Pulmonary Medicine 2011 11:23
  146. O’Shea SD, Taylor NF, Paratz JD. Progressive resistance exercise improves muscle strength and may improve elements of performance of daily activities for people with COPD: a systematic review. Chest. 2009 Nov;136(5):1269-83
  147. Ofir D, Laveneziana P, Webb KA, Lam Y-M, O’Donnell DE. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage 1 chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:622-62
  148. Oh H, Seo W. Meta-analysis of the effects of respiratory rehabilitation programmes on exercise capacity in accordance with programme characteristics. J Clin Nurs. 2007 Jan;16(1):3-15
  149. Ohar JA, Sadeghnejad A, Meyers DA, Donohue JF, Bleecker ER. Do symptoms predict COPD in smokers? Chest. 2010 Jun;137(6):1345-53
  150. Ohara T, Hirai T, Muro S, Haruna A, Terada K, Kinose D, Marumo S, Ogawa E, Hoshino Y, Niimi A, Chin K, Mishima M. Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD. Chest 2008 Dec;134(6):1244-9
  151. Oliveira CC, Lee A, Granger CL, Miller KJ, Irving LB, Denehy L. Postural control and fear of falling assessment in people with chronic obstructive pulmonary disease: a systematic review of instruments, international classification of functioning, disability and health linkage, and measurement properties. Arch Phys Med Rehabil. 2013 Sep;94(9):1784-1799.e7. doi: 10.1016/j.apmr.2013.04.012. Epub 2013 Apr 28.
  152. Oostenbrink JB, Rutten-van Molken MP, Al MJ, Van Noord JA, Vincken W. One-year cost-effectiveness if tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 2004 Feb;23(2):241-9
  153. Oostenbrink JB et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health. 2005 Jan-Feb;8(1):32-46
  154. Oraka E, Kim HJ, King ME, Callahan DB. Asthma prevalence among US elderly by age groups: age still matters. J Asthma. 2012 Aug;49(6):593-9. Epub 2012 Jul 6.
  155. Ospina MB, Voaklander DC, Stickland MK, King M, Senthilselvan A, Rowe BH. Prevalence of asthma and chronic obstructive pulmonary disease in Aboriginal and non-Aboriginal populations: A systematic review and meta-analysis of epidemiological studies. Can Respir J 2012;19(6):355-360
  156. Osthoff AK, Taeymans J, Kool J, Marcar V, van Gestel AJ. Association Between Peripheral Muscle Strength and Daily Physical Activity in Patients With COPD: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS. J Cardiopulm Rehabil Prev. 2013 Nov-Dec;33(6):351-9.
  157. Palwai A, Skowronski M, Coreno A, Drummond C, McFadden ER Jr. Critical comparisons of the clinical performance of oxygen-conserving devices. Am J Respir Crit Care Med. 2010 May 15;181(10):1061-71
  158. Park HY, Man SFP, Sin DD.  Inhaled corticosteroids for chronic obstructive pulmonary disease. BMJ 2012;345:e6843 doi: 10.1136/bmj.e6843 (Published 25 October 2012)
  159. Parker DR, Eaton CB, Ahern DK, Roberts MB, Rafferty C, Goldman RE, McCool D, Wroblewsk J. The study design and rationale of the randomized controlled trial: translating COPD guidelines into primary care practice. BMC Family Practice 2013, 14:56.
  160. Pascoe S, Reynolds C, Pleskow W, Perry S, Hmissi A, Kaiser G, Brookman L. Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily beta2-agonist bronchodilator, in subjects with COPD. Int J Clin Pharmacol Ther. 2011 Feb;49(2):153-61
  161. Pavasini R, d’Ascenzo F, Campo G, Biscaglia S, Ferri A, Contoli M, Papi A5 Ceconi C, Ferrari R. Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and meta-analysis. Int J Cardiol. 2015 Jul 15;191:187-93.
  162. Paz-Diaz H, Montes de Oca M, Lopez JM, Celli BR. Pulmonary rehabilitation improves depression, anxiety, dyspnea and health status in patients with COPD. Am J Phys Med Rehabil. 2007 Jan;86(1):30-6
  163. Pedone C, Scarlata S, Sorino C, Forastiere F, Bellia V, Antonelli R, Incalzi RA. Does mild COPD affect prognosis in the elderly? BMC Pulmonary Medicine 2010, 10:35 doi:10.1186/1471-2466-10-35
  164. Pepin V, Laviolette L, Brouillard C, Sewell L, Singh SJ, Revill SM, Lacasse Y, Maltais F. Significance of changes in endurance shuttle walking performance. Thorax. 2011 Feb;66(2):115-20
  165. Perez X, Wisnivesky JP, Lurslurchachai L, Kleinman LC, Kronish IM. Barriers to adherence to COPD guidelines among primary care providers. Respiratory Medicine 2012;106:374-381
  166. Pinner NA, Hamilton LA, Hughes A. Roflumilast: a phosphodiesterase‐4 inhibitor for the treatment of severe chronic obstructive pulmonary disease. Clinical Therapeutics.2012;34(1):56‐66
  167. Pinnock H, Kendall M, Murray SA, Worth A, Levack P, Porter M, MacNee W, Sheikh A. Living and dying with severe chronic obstructive pulmonary disease: multi-perspective longitudinal qualitative study. BMJ. 2011 Jan 24;342:d142. doi: 10.1136/bmj.d142
  168. Pison CM, Cano NJ, Cherion C, Caron F, Court-Fortune I, Antonini M-T, Gonzalez-Bermejo J, Meziane L, Molano LC, Janssens J-P, Costes F, Wuyam B, Similowski T, Melloni B, Hayot M, Augustin J, Tardif C, Lejeune H, Roth H, Pichard C, the IRAD Investigators. Multimodal nutritional rehabilitation improves clinical outcomes of malnourished patients with chronic respiratory failure: a randomised controlled trial. Thorax 2011;66:953e960. doi:10.1136/thx.2010.154922.
  169. Polkey MI, Spruit MA, Edwards LD, Watkins ML, Pinto-Plata V, Vestbo J, Calverley PMA, Tal-Singer R, Agusti A, Bakke PS, Coxson HO, Lomas DA, MacNee W, Rennard S, Silverman EK, Miller BE, Crim C, Yates J, Wouters EFM, Celli B on behalf of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Study Investigators. Six-minute walk test in COPD. Minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Medicine2013; 187(4):382-386.
  170. Postma DS, Anzueto AR, Jenkins C, Make BJ, Similowski T, Östlund O, et al. Factor analysis in predominantly severe COPD: identification of disease heterogeneity by easily measurable characteristics. Respir Med. 2013;107(12):1939-47.
  171. Postma DS, Brusselle G, Bush A, Holloway JW, I have taken my umbrella, so of course it does not rain. Thorax (2011). doi:10.1136/thoraxjnl-2011-200758
  172. Price LC, Lowe D, Hosker HS, Anstey K, Pearson MG, Roberts CM; British Thoracic Society and the Royal College of Physicians Clinical Effectiveness Evaluation Unit (CEEu). UK National COPD Audit 2003: Impact of hospital resources and organisation of care on patient outcome following admission for acute COPD exacerbation. Thorax 2006 Oct;61(10):837-42
  173. Price DB, Tinkelman DG, Halbert RJ, Nordyke RJ, Isonaka S, Nonikov D, Juniper EF, Freeman D, Hausen T, Levy ML, Ostrem A, van der Molen T, van Schayck CP. Symptom-based questionnaire for identifying COPD in smokers. Respiration 2006;73(3):285-95
  174. Probst VS, Kovelis D, Hernandes NA, Camillo CA, Cavalheri V, Pitta F. Effects of 2 exercise training programs on physical activity in daily life in patients with COPD. Respir Care. 2011 Nov;56(11):1799-807
  175. Puhan MA et al. How should COPD patients exercise during respiratory rehabilitation? Comparison of exercise modalities and intensities to treat skeletal muscle dysfunction. Thorax. 2005 May;60(5): 367-75
  176. Quintana JM, Esteban C, Unzurrunzaga A, Garcia-Gutierrez S, Gonzalez N, Barrio I, Arostegui I, Lafuente I, Bare M, Fernandez-de-Larrea N, Vidal S; IRYSS-COPD group. Predictive score for mortality in patients with COPD exacerbations attending hospital emergency departments. BMC Med. 2014 Apr 23;12:66. doi: 10.1186/1741-7015-12-66.
  177. Quon BS, Gan WQ, Sin DD. Contemporary management of acute exacerbations of COPD: A systematic review and metaanalysis. Chest 2008;133:756-766
  178. Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest. 2008 Aug;134(2):255-62
  179. Ram FS et al. Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Med. 2005 Feb;99(2):135-44
  180. Ram FSF, Brocklebank DM, Muers M, Wright J, Jones PW. Pressurised metered-dose inhalers versus all other hand-held inhaler devices to deliver bronchodilators for chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews: Reviews 2002 Issue 1 John Wiley & Sons, Ltd Chichester, UK DOI: 10.1002/14651858.CD002170
  181. Ram FS. Use of theophylline in chronic obstructive pulmonary disease: examining the evidence. Curr Opin Pulm Med 2006;12(2):132-9
  182. Rambod M, Porszasz J, Make BJ, Crapo JD, Casaburi R; COPDGene Investigators. Six-minute walk distance predictors, including CT scan measures, in the COPDGene cohort. Chest. 2012 Apr;141(4):867-75
  183. Ramırez-Venegas A, Sansores RH, Quintana-Carrillo RH, Velazquez-Uncal M, Hernandez-Zenteno RJ, Sanchez-Romero C, Velazquez-Montero A, Flores-Trujillo F. FEV1 Decline in Patients with Chronic Obstructive Pulmonary Disease Associated with Biomass Exposure. Am J Respir Crit Care Med 2014;190(9):996–1002
  184. Ramsey SD, Shroyer AL, Sullivan SD, Wood DE. Updated evaluation of the cost-effectiveness of lung volume reduction surgery. Chest 2007 Mar;131(3):823-32
  185. Ranes J and Stoller JK. A review of alpha-1 antitrypsin deficiency. Seminars in Respiratory and Critical Care Medicine 2005;26(2):154-166
  186. Rascon-Aguilar IE, Pamer M, Wludyka P, Cury J, Vega KJ. Poorly treated or unrecognized GERD reduces quality of life in patients with COPD. Dig Dis Sci. 2011 Jul;56(7):1976-80
  187. Reid DM, Devogelaer J-P, Saag K, Roux C, Lau C-S, Reginster J-Y, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN for the HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009;373:1253–63
  188. Reutman SR, Rohs AM, Clark JC, Johnson BC, Sammons DL, Toennis CA, Robertson SA, MacKenzie BA, Lockey JE. A pilot respiratory health assessment of nail technicians: symptoms, lung function, and airway inflammation. American Journal of Industrial Medicine 2009;52:868–875.
  189. Ribeiro M, Chapman KR. Comparative efficacy of indacaterol in chronic obstructive pulmonary disease. International Journal of COPD 2012:7 145–152
  190. Ricci C, Terzoni S, Gaeta M, Sorgente A, Destrebecq A, Gigliotti F. Physical training and non-invasive ventilation in stable chronic obstructive pulmonary disease patients: a meta-analysis and meta-regression. Respir Care. 2014 May;59(5):709-17.
  191. Richy F, Bousquet J, Ehrlich GE, Meunier PJ, Israel E, Morii H, Devogelaer J-P, Peel N, Haim M, Bruyere O, Reginster J-Y. Inhaled corticosteroid effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporosis Int. 2003;14:179-190
  192. Ringbaek TJ. Home oxygen therapy in COPD patients. Results from the Danish Oxygen register. Dan Med Bull. 2006;53(3):310-25
  193. Rizzi M, Grassi M, Pecis M, Andreoli A, Taurino AE, Sergi M, Fanfulla F. A specific home care program improves the survival of patients with chronic obstructive pulmonary disease receiving long term oxygen therapy. Arch Phys Med Rehabil. 2009 Mar;90(3):395-401
  194. Roberts CM, Stone RA, Buckingham RJ, Pursey NA, Lowe D, Potter JM. A randomized trial of peer review: the UK National Chronic Obstructive Pulmonary Disease Resources and Outcomes Project: three-year evaluation. J Eval Clin Pract. 2012 Jun;18(3):599-605. doi: 10.1111/j.1365-2753.2011.01639.x
  195. Roberts and Partridge. Evaluation of a paper and electronic pictorial COPD Action Plan. Chronic Resp Disease;8(1):31-40
  196. Rocker G, Young J, Donahue M, Farquhar M, Simpson C. Perspectives of patients, family caregivers and physicians about the use of opioids for refractory dyspnea in advanced chronic obstructive pulmonary disease. CMAJ. 2012 Jun 12;184(9):E497-504. Epub 2012 Apr 23.
  197. Rodrigo G, Pollack C, Rodrigo C, Rowe B, Walters EH. Heliox for treatment of exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2001, Issue 1. Art. No.: CD003571. DOI: 10.1002/14651858.CD003571
  198. Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest. 2008 May;133(5):1079-87
  199. Rodrigo GJ, Nannini LJ. Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis. Pulm Pharmacol Ther. 2007;20(5):495-502. Epub 2006 Mar 2
  200. Rodrigo GJ, Plaza V, Castro‐Rodriguez JA. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. Pulmonary Pharmacology and Therapeutics.2012;25(1):40‐47
  201. Rodríguez-Roisin R. COPD exacerbations · 5: Management. Thorax 2006;61;535-544
  202. Rootmensen GN, van Keimpema AR, Looysen EE, van der Schaaf L, de Haan RJ, Jansen HM. The effects of additional care by a pulmonary nurse for asthma and COPD patients at a respiratory outpatient clinic: results from a double blind, randomized clinical trial. Patient Educ Couns. 2008 Feb;70(2):179-86. Epub 2007 Nov 26
  203. Rose C, Wallace L, Dickson R, Ayres J, Lehman R, Searle Y, Burge PS. The most effective psychologically-based treatments to reduce anxiety and panic in patients with chronic obstructive pulmonary disease (COPD): a systematic review. Patient Education and Counseling 2002;47(4):311-318
  204. Rossi A, Centanni S, Cerveri I, Gulotta C, Foresi A, Cazzola M, Brusasco V. Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. Respir Med. 2012 Jan;106(1):84-90
  205. Rossi A, Polese G. Indacaterol: a comprehensive review. International Journal of COPD 2013:8 353–363.
  206. Rossi A, Guerriero M, Corrado A, Group OAS. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res. 2014;15:77.
  207. Rothberg MB, Pekow PS, Lahti M, Brody O, Skiest DJ, Lindenauer PK. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA. 2010 May 26;303(20):2035-42
  208. Runciman W et al. Care Track: Assessing the appropriateness of health care delivery in Australia. MJA 197(2) 16 July 2012: 100-105.
  209. Russi EW, Karrer W, Brutsche M, Eich C, Fitting JW, Frey M, Geiser T, Kuhn M, Nicod L, Quadri F, Rochat T, Steurer-Stey C, Stolz D; Swiss Respiratory Society. Diagnosis and management of chronic obstructive pulmonary disease: the Swiss guidelines. Official guidelines of the Swiss Respiratory Society. Respiration. 2013;85(2):160-74. doi: 10.1159/000346025. Epub 2013 Feb 11.